top of page

Cardea Bio Adds $6.5 Million to Series A; Early-Stage Financing Now Totals More Than $20 Million

Jan 12, 2021

-Cardea Bio, Inc., a Tech+Bio company integrating molecular biology with semiconductors via Graphene-based biology-gated Transistors, announced today a $6.5M series A extension that brings the A round total above $20M. The new capital infusion is led by the life sciences and biotechnology focused investor 3E Bioventures Capital and joined by existing investors. Proceeds from the financing will be used to further develop Cardea’s proprietary Transistor platform, in order to significantly expand mass-manufacturing and further grow Cardea’s number of commercial partnerships.


The Art of Capturing Beauty at the Nanoscale

bottom of page